Status:
ACTIVE_NOT_RECRUITING
Extended Follow-up of Women Who Received One, Two, and Three Doses of the HPV Vaccine in the Costa Rica Vaccine Trial (CVT), ESCUDDO-CVT Study
Lead Sponsor:
National Cancer Institute (NCI)
Conditions:
Human Papillomavirus Infection
Human Papillomavirus-Related Malignant Neoplasm
Eligibility:
FEMALE
Brief Summary
This study is extending follow up of women who participated in the Costa Rica Vaccine Trial (CVT) and received one dose or two doses of the human papillomavirus (HPV) vaccine, along with a group of wo...
Detailed Description
PRIMARY OBJECTIVES: I. Estimate the change in antibody levels between years 11 and 20. II. Estimate the proportion of individuals who become seronegative (i.e.: serorevert) between years 11 and 20. ...
Eligibility Criteria
Inclusion
- Participation in the CVT Long Term Follow-Up (LTFU) study
Exclusion
- A random subset of the three-dose women
Key Trial Info
Start Date :
July 2 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 28 2026
Estimated Enrollment :
991 Patients enrolled
Trial Details
Trial ID
NCT03309033
Start Date
July 2 2018
End Date
February 28 2026
Last Update
July 23 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Agencia Costarricense de Investigaciones Biomédicas (ACIB)
Liberia, Guanacaste Province, Costa Rica, 50101